Conv. Plasma
Nigella Sativa

All favipiravir studies
Meta analysis
study COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Oxygen therapy -1% Improvement Relative Risk Hospitalization -56% Favipiravir  McMahon et al.  EARLY TREATMENT  RCT Is early treatment with favipiravir beneficial for COVID-19? RCT 199 patients in Australia (July 2020 - September 2021) Higher hospitalization with favipiravir (not stat. sig., p=0.38) McMahon et al., eClinicalMedicine, Jun 2022 Favors favipiravir Favors control

Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial

McMahon et al., eClinicalMedicine, doi:10.1016/j.eclinm.2022.101703, NCT04445467
Jun 2022  
  Source   PDF   All   Meta
RCT with 99 favipiravir and 100 placebo patients in Australia, all except one being outpatients, showing no significant differences with treatment.
risk of oxygen therapy, 1.0% higher, RR 1.01, p = 1.00, treatment 6 of 99 (6.1%), control 6 of 100 (6.0%).
risk of hospitalization, 55.6% higher, RR 1.56, p = 0.38, treatment 14 of 99 (14.1%), control 9 of 99 (9.1%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
McMahon et al., 14 Jun 2022, Randomized Controlled Trial, placebo-controlled, Australia, peer-reviewed, median age 36.0, 33 authors, study period 31 July, 2020 - 19 September, 2021, trial NCT04445467 (history). Contact:
This PaperFavipiravirAll
Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial
James H Mcmahon, Jillian S Y Lau, Anna Coldham, Janine Roney, Michelle Hagenauer, Sally Price, Mellissa Bryant, Jill Garlick, Anne Paterson, Sue J Lee, Jess O'bryan, Anna Hearps, Gilda Tachedjian, Henry Pinskier, Cameron Phillips, Stuart Garrow, Nathan Pinskier, Robert Melvin, Luke Blakeway, Jessica A Wisniewski, Sally Byers, Gnei Z Badoordeen, Stephanie Pereira, Katherine Pragastis, Jason A Trubiano, Kyra Y L Chua, Marion Kainer, James S Molton, Bradley J Gardiner, Anna B Pierce, Allen Cheng, Benjamin A Rogers, Anton Y Peleg
eClinicalMedicine, doi:10.1016/j.eclinm.2022.101703
Background Well tolerated antivirals administered early in the course of COVID-19 infection when the viremia is highest could prevent progression to severe disease. Favipiravir inhibits SARS-CoV-2 viral replication in vitro with evidence of clinical benefit in open label trials. Placebo controlled studies of people with early symptomatic COVID-19 with regular assessments of SARS-CoV-2 viral load can determine if it has an antiviral effect and improves clinical outcomes. Methods People with PCR-confirmed COVID-19 and 5 days or less of symptoms were randomised 1:1 to favipiravir 1800 mg on day 1, then 800 mg twice daily or matched placebo for 14 days. SARS-CoV-2 viral load was quantitated from second daily self-collected nose-throat swabs while receiving study drug. The primary endpoint was time to virological cure defined as 2 successive swabs negative for SARS-CoV-2 by PCR and secondary outcomes were progression of disease severity, symptom resolution and safety.
Contributors JHM and AYP conceptualized and designed the study. SJL, JHM and AYP analysed and interpreted the data and drafted the figures and tables. JHM JSYL, BR, AC, SJL and AYP drafted the protocol. JHM acquired the funding. AC, JR, MB, SP, JG, MH, JO'B, AP collected and entered the data and administered the project. AH and GT designed and performed the virological analyses. LB, JAW, SB, GZB, SP ad KP collected and processed all study specimens. HP, SG, NP, CP, RM, BR, JT, KC, MK, JM, AP, BG and JSYL identified study participants for enrolment. JHM and JSYL consented participants, performed study procedures and assessments of adverse effects. JHM wrote the first draft of the manuscript. All authors contributed, reviewed and edited the manuscript. Data sharing statement Anonymized raw data will be available upon a written request to the corresponding author. The data will be shared with requesters after approval and a signed datasharing agreement between the requester and the sponsor Alfred Health. Declaration of interests All authors declare no competing interests. Supplementary materials Supplementary material associated with this article can be found in the online version at doi:10.1016/j. eclinm.2022.101703.
Bernal, Da Silva, Musungaie, Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients, N Engl J Med
Biancofiore, Mirijello, Puteo, Remdesivir significantly reduces SARS-CoV-2 viral load on nasopharyngeal swabs in hospitalized patients with COVID-19: a retrospective case-control study, J Med Virol
Bosaeed, Alharbi, Mahmoud, Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial, Clin Microbiol Infect
Cai, Yang, Liu, Experimental treatment with favipiravir for COVID-19: an open-label control study, Engineering (Beijing
Cevik, Kuppalli, Kindrachuk, Peiris, Virology, transmission, and pathogenesis of SARS-CoV-2, BMJ
Chen, Zhang, Huang, Favipiravir versus arbidol for clinical recovery rate in moderate and severe adult COVID-19 patients: a prospective, multicenter, open-label, randomized controlled clinical trial, Front Pharmacol
Chuah, Chow, Hor, Efficacy of early treatment with favipiravir on disease progression among high risk COVID-19 patients: a randomized, open-label clinical trial, Clin Infect Dis
Doi, Hibino, Hase, A prospective, randomized, openlabel trial of early versus late favipiravir therapy in hospitalized patients with COVID-19, Antimicrob Agents Chemother
Driouich, Cochin, Lingas, Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model, Nat Commun
Furuta, Takahashi, Kuno-Maekawa, Mechanism of action of T-705 against influenza virus, Antimicrob Agents Chemother
Gottlieb, Vaca, Paredes, Early remdesivir to prevent progression to severe Covid-19 in outpatients, N Engl J Med
Group, Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial, Lancet
Group, Horby, Lim, Dexamethasone in hospitalized patients with Covid-19, N Engl J Med
Group, Horby, Mafham, Effect of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med
Gupta, Gonzalez-Rojas, Juarez, Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial, JAMA
Hammond, Leister-Tebbe, Gardner, Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19, N Engl J Med
Holubar, Subramanian, Purington, Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial, Clin Infect Dis
Lingas, Neant, Gaymard, Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial, J Antimicrob Chemother
Lu, Wang, Sakthivel, US CDC real-time reverse transcription PCR panel for detection of severe acute respiratory syndrome coronavirus 2, Emerg Infect Dis
Marconi, Ramanan, De Bono, Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial, Lancet Respir Med
Mcmahon, Lau, Roney, An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): a structured summary of a study protocol for a randomised controlled trial, Trials
Reis, Silva, Silva, Effect of early treatment with ivermectin among patients with Covid-19, N Engl J Med
Shannon, Selisko, Le, Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis, Nat Commun
Sissoko, Laouenan, Folkesson, Experimental treatment with favipiravir for ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea, PLoS Med
Takashita, Kinoshita, Yamayoshi, Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2, N Engl J Med
Udwadia, Singh, Barkate, Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, openlabel, multicenter, phase 3 clinical trial, Int J Infect Dis
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop